Last reviewed · How we verify
Lipid-lowing Tea
Lipid-lowing Tea is a Herbal/botanical lipid-lowering agent Small molecule drug developed by China Medical University Hospital. It is currently in Phase 3 development for Hyperlipidemia/dyslipidemia.
A lipid-lowering herbal tea formulation that reduces serum lipid levels through bioactive compounds.
A lipid-lowering herbal tea formulation that reduces serum lipid levels through bioactive compounds. Used for Hyperlipidemia/dyslipidemia.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Cardiovascular Phase 3 risk
-2.0pp
Modern cardiovascular outcome trials are large + long; many fail to beat aggressive standard-of-care.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Lipid-lowing Tea |
|---|---|
| Sponsor | China Medical University Hospital |
| Drug class | Herbal/botanical lipid-lowering agent |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Lipid-lowering tea typically contains polyphenols, catechins, and other plant-derived compounds that may inhibit cholesterol absorption, enhance lipid metabolism, or reduce hepatic lipid synthesis. The exact mechanism depends on the specific tea components and their interactions with lipid metabolism pathways.
Approved indications
- Hyperlipidemia/dyslipidemia
Common side effects
- Gastrointestinal upset
- Caffeine-related effects
Key clinical trials
- The Clinical Evaluation of Efficacy of Lipid-Lowing Tea on Hyperlipidemia Patients' Lipid Profiles (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lipid-lowing Tea CI brief — competitive landscape report
- Lipid-lowing Tea updates RSS · CI watch RSS
- China Medical University Hospital portfolio CI
Frequently asked questions about Lipid-lowing Tea
What is Lipid-lowing Tea?
How does Lipid-lowing Tea work?
What is Lipid-lowing Tea used for?
Who makes Lipid-lowing Tea?
What drug class is Lipid-lowing Tea in?
What development phase is Lipid-lowing Tea in?
What are the side effects of Lipid-lowing Tea?
Related
- Drug class: All Herbal/botanical lipid-lowering agent drugs
- Manufacturer: China Medical University Hospital — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Hyperlipidemia/dyslipidemia
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing